Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Disaggregation of Revenue [Line Items]
Net Revenue	$ 15,927	$ 28,316	$ 50,912	$ 76,824
Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	0	11	325	34
Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	15,927	28,305	50,587	76,790
U.S.
Disaggregation of Revenue [Line Items]
Net Revenue	13,824	26,247	44,449	70,390
U.S. | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	0	0	0	0
U.S. | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	13,824	26,247	44,449	70,390
Rest of World
Disaggregation of Revenue [Line Items]
Net Revenue	2,103	2,069	6,463	6,434
Rest of World | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	0	11	325	34
Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	2,103	2,058	6,138	6,400
License Fee – Over Time | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	0	11	325	34
License Fee – Over Time | U.S. | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	0	0	0	0
License Fee – Over Time | Rest of World | Drug Revenues
Disaggregation of Revenue [Line Items]
Net Revenue	0	11	325	34
Product Sales – Point-in-time | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	15,927	28,305	50,587	76,790
Product Sales – Point-in-time | U.S. | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	13,824	26,247	44,449	70,390
Product Sales – Point-in-time | Rest of World | Concentrate Products
Disaggregation of Revenue [Line Items]
Net Revenue	$ 2,103	$ 2,058	$ 6,138	$ 6,400